An integrated structural and biophysical approach to study carbon metabolism in *Mycobacterium tuberculosis*

Evelyn Y.-W. Huang,[1] Francis Kuang,[1] Haozhe Wu,[1] Chai Xin Yu,[1] Xiaoxu Chen,[1] Glenda Vasku,[1] Le Thao Anh Nguyen,[1] Katherine J. Jeppe,[2] Anna K. Coussens,[3,4] Brooke X. C. Kwai,[5]* Ivanhoe K. H. Leung[1]*

1. School of Chemistry and Bio21 Molecular Science & Biotechnology Institute, The University of Melbourne, Parkville, Victoria, Australia.

2. Monash Proteomics and Metabolomics Platform, Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Victoria, Australia.

3. Infectious Diseases and Immune Defence Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia

4. Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia.

5. Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.

* Email: brooke.kwai@monash.edu, ivanhoe.leung@unimelb.edu.au

Abstract

Metabolic enzymes are the catalysts that drive the biochemical reactions that are essential for sustaining life. Many of these enzymes are tightly regulated by feedback mechanisms. To fully understand their roles and modulation, it is crucial to investigate the relationship between their structure, catalytic mechanism, and function. In this perspective, by using three examples from our studies on *Mycobacterium tuberculosis* (*Mtb*) isocitrate lyase and related proteins, we highlight how an integrated approach combining structural, activity and biophysical data provides insights into their biological functions. These examples underscore the importance of employing fast-fail experiments at the early stages of a research project, emphasise the value of complementary techniques in validating findings, and demonstrate how *in vitro* data combined with chemical, biochemical and physiological knowledge can lead to a broader understanding of metabolic adaptations in pathogenic bacteria. Finally, we address the unexplored questions in *Mtb* metabolism and discuss how we expand our approach to include microbiological and bioanalytical techniques to further our understanding. Such an integrated and interdisciplinary strategy has the potential to uncover novel regulatory mechanisms and identify new therapeutic opportunities for the eradication of tuberculosis. The approach can also be broadly applied to investigate other biochemical networks and complex biological systems.

Introduction

Metabolic enzymes are the catalysts that drive the chemistry of life. Seamlessly integrated into every metabolic pathway and cycle, they play pivotal roles in supporting the complex biochemistry of the cell, from enabling the reactions that convert nutrients into energy to facilitating the synthesis of molecules that are essential for sustaining life (Nielsen, 2017). Inside the cell, metabolic processes are inherently dynamic (Chubukov et al., 2014; Desvergne et al., 2006). They constantly adjust and coordinate with one another to meet the cell's needs and respond to changes in the environment. This dynamism is, in part, driven by the actions of metabolic enzymes. For example, many of these enzymes are regulated through intricate positive and negative feedback mechanisms, which enable them to orchestrate the flux of reactions both within and across different metabolic pathways (Locasale, 2018; Ye and Medzhitov, 2019). Hence, to fully understand cellular metabolism, we must not only examine the functions of metabolic enzymes but also investigate how these enzymes, themselves, are regulated.

Over the years, numerous methods have been applied to study metabolic enzymes. Early efforts have focused on isolating enzymes from different organisms to characterise the chemical reactions that they catalyse (Volesky et al., 1984). In recent decades, advances in molecular biology and genetics have enabled knockout or mutagenesis studies to be performed, which have provided valuable insights into the essentiality of metabolic enzymes and the biochemical pathways that they control (Long and Antoniewicz, 2014). However, these approaches provide little details about how these enzymes function, their mechanisms of action, and the factors that regulate their activity.

The function, catalytic activity, and specificity of metabolic enzymes are governed by their three-dimensional structure and their interactions with substrates and ligands. Hence, to complete this intricate picture, structural biology techniques (Dobson 2019; Subramaniam and

Kleywegt, 2022) and biophysical tools (Santiveri et al., 2017; Zhao et al., 2024) are essential. Structural biology techniques enable the visualisation of protein structures, dynamics, and oligomeric states, while biophysical tools allow intermolecular interactions and reaction kinetics to be studied (Figure 1). These approaches not only reveal the physical and dynamic properties of enzymes but also provide critical insights into their mechanistic roles. For metabolic enzymes that are linked to a certain disease's pathogenesis, greater understanding of these aspects opens unexplored avenues for therapeutic intervention.

<INSERT FIGURE 1 HERE>

Figure 1: Integrated biophysical and structural approach to studying metabolic enzymes. Our approach combines various biophysical and structural methods to investigate metabolic enzymes. These techniques differ in throughput, precision, and the level of detail that they provide. By strategically employing them at different stages of a project, we gather complementary insights that enhance our understanding of the function and mechanism of the enzyme target.

Our laboratory studies the carbon metabolism of *Mycobacterium tuberculosis* (*Mtb*), the bacterium that causes tuberculosis (TB). We began our journey eight years ago, embarking on a mechanistic enzymology study of *Mtb* isocitrate lyase (ICL) isoform 2 (Bhusal et al., 2019); at that time defined as a "barely active but essential" metabolic enzyme whose roles were not understood at the molecular level (Muñoz-Elías and McKinney, 2005) (see below for more information). By integrating different biophysical and structural techniques, we have made key discoveries on *Mtb* ICL2 along the way (Bhusal et al., 2017b; Bhusal et al., 2019; Huang et al., 2023; Kwai et al., 2021). In this perspective, we reflect on our journey by highlighting three distinct stories that exemplify our approach to uncover the function, regulation, and interactions of *Mtb* ICL2. We also demonstrate how we have used this combined biophysical and structural data to systematically address discrepancies in the existing literature, including their function, inhibition and interactions with other biomolecules. Finally, we discuss the unresolved challenges in understanding the regulation of *Mtb* carbon metabolism and outline the value we

have experienced from forming synergistic collaborations with *Mtb* microbiologists and bioanalytical chemists to broaden the scope of our research as our ongoing and future work. We hope the stories about our journey will inspire others to use similar integrated approaches when studying enzymes to understand their roles in their respective biochemical pathways and networks and thereby their contributions to an organisms homeostatic and disease states.

The system of interest: *Mtb* enzymes at the tricarboxylic acid cycle-glyoxylate shunt junction

Mtb is a highly successful pathogen that has evolved alongside humans for millennia (Saelens et al., 2019). Primarily an obligate intracellular pathogen, a defining characteristic of *Mtb* is its ability to evade and counter a multitude of antibacterial mechanisms activated by the phagocytic immune cells that it infects. In doing so, *Mtb* can persist intracellularly within the infected host for years or even decades (Ehrt et al., 2018; Gomez and McKinney, 2004). During chronic infection, *Mtb* primarily resides within the phagosomes of macrophages, where the amount and sources of essential nutrients that are required to sustain microbial life are limited (Ahmad et al., 2022; Russell et al., 2010). For example, glucose, the primary carbon source for many bacteria, is not directly available in high concentrations. Other carbon-based nutrients, such as amino acids, fatty acids and cholesterol, may also fluctuate in their availability depending on the metabolic state of the macrophage (Appelberg 2006; Laval et al., 2021). Besides nutrient availability, the environment inside the infected macrophage also presents numerous stressors, such as acidic pH, hypoxia and iron restriction (Rodriguez et al., 2022; Vieira et al., 2002).

Nonetheless, *Mtb* survives under these challenging conditions. One of the reasons for this remarkable resilience is its highly flexible and tightly controlled primary metabolism (Mashabela et al., 2019; Park et al., 2021; Rhee et al., 2011; Warner, 2015). Unlike most bacterial pathogens that can consume only one carbon source at a time, *Mtb* can utilise multiple

carbon sources simultaneously (Borah et al., 2021; de Carvalho et al., 2010). This capacity enables *Mtb* to maximise nutrient utilisation in a nutrient-deprived environment, thereby enhancing its ability to withstand environmental fluctuations, including nutrient availability. Whilst this unique adaptation is recognised, the molecular mechanisms controlling this capability have been poorly understood. This hinders our ability to develop new treatments to target *Mtb* metabolism for novel anti-TB therapies.

Our research focuses on the junction between the tricarboxylic acid (TCA) cycle and the glyoxylate shunt (Figure 2a). The two enzymes that are present in this metabolic node is ICL and isocitrate dehydrogenase (ICD) (Figure 2b). ICD is a TCA cycle enzyme that catalyses the oxidation of isocitrate to form 2-oxoglutarate and carbon dioxide, a reaction that is coupled with the reduction of nicotinamide adenine dinucleotide phosphate ($NADP^+$) to NADPH. ICL is the first enzyme in the glyoxylate shunt. It catalyses the conversion of isocitrate to form succinate and glyoxylate.

The TCA cycle is the central metabolic pathway that is used by all aerobic organisms for cellular energy production and biosynthesis (Akram, 2014) (Figure 2a). It breaks down acetyl-coenzyme A (acetyl-CoA) to release energy in the form of high-energy molecules such as adenosine triphosphate (ATP). During this process, two molecules of carbon dioxide are produced as byproducts. While this cycle is very efficient in producing high-energy molecules to support cellular functions, it is also relatively 'wasteful' as two carbon atoms are lost for each acetyl-CoA molecule.

The glyoxylate shunt, in contrast, is a pathway that branches across the TCA cycle to bypass the two oxidative decarboxylation steps (Dolan and Welch, 2018) (Figure 2a). This pathway is absent from humans, but is present in many bacteria including *Mtb*, and it is advantageous for bacteria when growing on some non-carbohydrate carbon substrates (such as fatty acids), as the carbon atoms that would otherwise be lost as carbon dioxide can be preserved for purposes

such as gluconeogenesis. It is worth noting, however, that the glyoxylate shunt has been implicated in other physiologically relevant conditions in *Mtb*. Aside from the metabolism of fatty acids, the glyoxylate shunt enzyme ICL enables the detoxification of propionate-derived intermediates through its dual function as a methylisocitrate lyase (Gould et al., 2006; Muñoz-Elías et al., 2006), and this added role was also utilised for lactate and pyruvate metabolism (Serafini et al., 2019; Borah et al., 2021). Beyond carbon metabolism, the glyoxylate shunt has also been highlighted for its other roles in *Mtb* such as its persistence inside macrophages (McKinney et al., 2000), adaptation to hypoxia (Eoh and Rhee, 2013), and antibiotic resistance (Nandakumar, Nathan, and Rhee, 2014). The glyoxylate shunt also enables *Mtb* to grow on odd-chain substrates and precursors such as sterols (e.g., cholesterols), odd-chain or uneven branched-chain fatty acids, and amino acids. This is because, in *Mtb*, ICLs are dual function enzymes (Gould et al., 2006; Muñoz-Elías et al., 2006). Not only *Mtb* ICLs compete with the TCA cycle for the substrate isocitrate, but they also assume the role of methylisocitrate lyases to break down 2-methylisocitrate. This step is essential in the methylcitrate cycle for the detoxification of propionyl-CoA, which is derived from odd-chain carbon substrates. Interestingly, recent studies suggest that the glyoxylate shunt is also crucial for the reverse methylcitrate cycle, which produces propionyl-CoA for odd-chain fatty acid synthesis when carbon substrates such as lactate or pyruvate were used (Serafini et al., 2019; Borah et al., 2021). Thus, rather than serving merely as an anaplerotic pathway, the glyoxylate shunt plays key roles in regulating carbon metabolic flux in *Mtb* under different conditions by interfacing with multiple connected metabolic pathways.

We, as well as others (Chang and Guan, 2021; Marrero et al., 2010; Xu et al., 2022), have hypothesised that the regulation of carbon flux at the intersection between the TCA cycle and the glyoxylate shunt is highly relevant to the ability of *Mtb* to persist inside macrophages. As *Mtb* can metabolise different types of carbon substrates simultaneously, the flow of carbon at

this junction must be controlled so physiological processes such as energy production and biosynthesis can be balanced.

<INSERT FIGURE 2 HERE>

Figure 2: The TCA cycle and the glyoxylate shunt. *(a) The TCA cycle (in black), through a number of steps, breaks down and oxidises acetyl-CoA to generate high-energy intermediates such as ATP, while the glyoxylate shunt (in red) diverts the flow of carbon away from the two oxidative decarboxylation steps of the TCA cycle. The conversion of 2-oxoglutarate to succinate can occur via different pathways in Mtb (Baughn et al., 2009; Tian et al., 2005; Wagner et al., 2011), so it is illustrated here as a single reaction from 2-oxoglutarate to succinate, rather than a conversion through succinyl-CoA that is present in many other organisms ; (b) The enzymes ICD and ICL are positioned at the junction between the TCA cycle and the glyoxylate shunt. ICD catalyses the oxidative decarboxylation of isocitrate to form 2-oxoglutarate and carbon dioxide, while ICL catalyses the cleavage of isocitrate to form succinate and glyoxylate.*

Since ICD and ICL compete for the same substrate, isocitrate, their relative activities are likely to be critical in regulating carbon flux at this junction. However, the mechanisms underlying this regulation in *Mtb* remain poorly understood. For example, *Mtb* does not possess the protein kinase (aceK isocitrate dehydrogenase kinase/phosphatase) that regulates ICD activity in other bacteria, such as *Escherichia coli* (Dolan and Welch, 2018). In addition, *Mtb* possesses two isoforms of ICL (Bhusal et al., 2017a; Muñoz-Elías and McKinney, 2005) and two isoforms of ICD (Banerjee et al., 2005), but their relative roles in *Mtb* carbon metabolism are not clear. Although both *Mtb* ICL1 and ICL2 have been shown to be essential to the virulence and survival of the bacterium during infection, *in vitro* activity assays have shown that ICL2 was barely active (Muñoz-Elías and McKinney, 2005). These unknowns in *Mtb* metabolism piqued our interest when we first embarked on this research, prompting us to investigate the enzymes of this critical junction further.

Prerequisite: having the right tool for the task

One of the most overlooked aspects of a successful research project is to have the right tools for the tasks at hand. For enzyme studies, these tools include experiments to assay enzyme

activity, methods to monitor interactions with other (bio)molecules, and structural techniques to visualise protein structures. We are fortunate to have access to a wide range of techniques at our institute, which allows us to select the most suitable methods, or, in many cases, a combination of complementary approaches, to answer our research questions (Figure 1). Nonetheless, the principles outlined in this perspective can be applied across laboratories of all sizes and configurations, with access facilitated through local, national, and international collaborations.

Enzyme kinetics

For enzyme kinetic analyses, two main types of assays are typically employed. The first are spectrophotometry-based assays, which track reaction kinetics by monitoring changes in absorbance or fluorescence. These assays are among the earliest reported in the literature and are widely used for studying ICL- and ICD-catalysed reactions across all/diverse taxa. For example, ICD activity can be measured spectrophotometrically at 340 nm (Nachlas et al., 1963; Rokosh et al., 1973), which corresponds to the formation of NADPH. Similarly, ICL activity can be monitored by reacting the product glyoxylate with phenylhydrazine to form a phenylhydrazone adduct, which absorbs at 324 nm (Dixon and Kornberg, 1959). The advantage of indirect assays lies in their efficiency, simplicity and accessibility. Once calibration and optimisation of the derivatisation steps (if needed) are completed, these assays can be readily adapted to a plate format to support high-throughput applications (Nakayama, 1998; Sittampalam et al., 1997).

The second type of assays are spectroscopic/spectrometric methods such as mass spectrometry (Greis, 2007; Sharma et al., 2021) or nuclear magnetic resonance (NMR) spectroscopy (Bhusal et al., 2017b; Vang et al., 2022), which allow substrates and/or products to be measured and characterised directly. Compared to spectrophotometry-based assays, these methods provide a more detailed chemical and/or structural information about the substrate and products. While

these approaches may involve additional complexities, such as the need for specialised expertise and tailored optimisation for each enzyme system, they offer unique opportunities for in-depth mechanistic studies. Mass spectrometry allows the use of various ionisation techniques to isolate diverse substrates and products (El-Aneed et al., 2009), and the integration of chromatography can further enhance analyte separation (de Boer et al., 2004). Hence, while these spectroscopic/spectrometric methods offer greater specificity and accuracy, their application requires careful consideration of the experimental setup. These additional requirements make these assays more resource-intensive (in terms of time, human resource and reagents) but beneficial for detailed mechanistic studies and comprehensive characterisation of enzymatic systems.

When studying a new enzyme system, it is crucial to understand its behaviour and fully characterise the reaction and its components. For this reason, we avoid relying on spectrophotometry-based assays during the initial stages of our work. Instead, we prioritise techniques such as NMR spectroscopy as it provides more details on the reaction components (e.g., substrates and products) rather than a mere change in colour or wavelength. In ICD-catalysed reactions, ^{1}H NMR allows us to visualise and quantify both NADP$^+$ reduction and the turnover of isocitrate to 2-oxoglutarate (Figure 3a). This precise and complementary information not only helps us to elucidate the reaction mechanism (e.g., coupling between the two steps, Figure 3b) but also minimises the risk of misinterpreting data. Although both spectrophotometry and spectroscopy-based assays are susceptible to interferences (such as changes in temperature or air bubbles), distinguishing between interference and enzyme-specific reactions is more challenging with spectrophotometry-based assays. In contrast, spectroscopy-based assays such as NMR offer molecular-level details that help differentiate between these effects. For instance, in one of our earlier studies on a human metabolic enzyme (BBOX, which is involved in carnitine biosynthesis), a previously unrecognised enzymatic

reaction involving an enzyme inhibitor was identified using NMR spectroscopy (Leung et al., 2010) while prior work relying on less-informative methods had incorrectly characterised the compound as a non-substrate (Spaniol et al., 2001) or even as a non-competitive inhibitor (Galland et al., 1998; Simkhovich et al., 1988). However, as spectroscopy/spectrometry-based assays are time-consuming, once we have established a robust understanding of the enzyme system and its assay conditions, we typically transition to spectrophotometry. These are more suitable for larger-scale and higher-throughput analyses of kinetic parameters.

<INSERT FIGURE 3 HERE>

Figure 3: ^{1}H NMR-based enzyme assays. (a) Information-rich assays, such as ^{1}H NMR spectroscopy, allow simultaneous monitoring of substrate and co-substrate turnover in real time. This facilitates the optimisation of the enzyme system before transitioning to higher-throughput assays for measurements like kinetic parameters. In the example shown here, the turnover of $NADP^+$ to NADPH and the decarboxylation of isocitrate to 2-oxoglutarate can be measured in the same spectrum; (b) Illustrative time course of the Mtb ICD-catalysed reaction. Reaction mixture included 200 nM ICD2, 8 mM DL-isocitrate, 4 mM $NADP^+$, 5 mM $MgCl_2$, 0.02% NaN_3, 50 mM Tris-d_{11} (pH 7.5) in 90% H_2O and 10% D_2O. The data was collected using a 700 MHz Bruker Avance IIIHD spectrometer with TCI cryoprobe.

Protein-ligand interactions

In addition to studying enzyme kinetics, we also employ a range of biophysical techniques to monitor protein-ligand binding interactions. For non-covalent interactions, multiple methods are available. Similar to the described activity assays, these methods provide varying levels of information. Indirect techniques, such as thermal shift assays that measure deviations in protein thermal stability upon ligand addition, are high throughput but less precise (Huynh and Partch, 2015). This limitation arises because the relationship between ligand binding and protein stability is neither direct nor linear (Celej et al., 2003). Nevertheless, the widespread availability of equipment like thermal cyclers in most biochemistry laboratories makes this method a popular choice. However, the results obtained from these indirect measurements must be interpreted with care and, where possible, validated with another experimental technique.

In contrast, direct binding techniques such as isothermal titration calorimetry (Bastos et al., 2023; Velázquez-Campoy et al., 2004), surface plasmon resonance (Pattnaik, 2005), intrinsic fluorescence spectroscopy (Leung et al., 2021; Ward, 1985), and both ligand- and protein-observed NMR spectroscopy (Krimm, 2017; Mbenza et al., 2017) offer more accurate measurements. These techniques vary in throughput but provide deeper insights into the binding interactions (e.g., binding affinity and, in some instances, information about binding sites). In addition, specialised methods like mass photometry (Asor and Kukura, 2022) and analytical ultracentrifugation (Dobson and Patel, 2020; Howlett et al., 2006) are useful for characterising interactions with proteins or larger biomolecules. As such, we ensure at least one of these methods is used when we want to study protein-ligand interactions. However, many of these techniques (with the possible exception of intrinsic fluorescence measurements) require specialised equipment. They also necessitate optimisation for each protein system. Hence, the adoption of these techniques is less straightforward.

Apart from non-covalent interactions, covalent interactions also offer some analytical challenges. We typically use whole-protein mass spectrometry under denaturing conditions to monitor protein mass shifts to confirm the modification (Compton et al., 2011), and tandem mass spectrometry following proteolysis to confirm the modification site on the protein (Cottrell, 2011).

When studying binding interactions, one must be cognisant to select the techniques that are compatible with the enzyme system of interest and capable of detecting interactions within the relevant affinity range. Where possible, following technique selection, we will optimise the binding experiments using a model ligand system, such as a substrate analogue or a known enzyme inhibitor, and perform all necessary controls, including competition assays, before investigating unknown interactions. Although time consuming, performing these controls ensures the reliability and accuracy of the results, and minimises the risk of artefacts or non-

specific effects causing misinterpretation of binding data. This meticulous approach is essential for drawing meaningful conclusions, particularly when exploring a new or complex protein-ligand systems.

Structural and biophysical properties

Finally, structural information is also essential for understanding enzyme function and regulation. For this, we typically use structural techniques such as protein X-ray crystallography and cryo-electron microscopy to determine high-resolution protein structures (Renaud et al., 2018; Shoemaker and Ando, 2018; Wang and Wang, 2016). However, as enzymes and proteins are inherently dynamic, we also employ complementary biophysical techniques such as small-angle X-ray scattering (SAXS) (Schneidman-Duhovny and Hammel, 2018), protein NMR spectroscopy (Boehr et al., 2006; Ishima and Torchia, 2000), and circular dichroism (CD) spectroscopy (Miles et al., 2021) to study their dynamic behaviour or changes in structure or structural components. It is important to note that each of these techniques has their own advantages and limitations as they provide different levels of resolution and information. For example, while protein NMR is useful in studying protein dynamics, it can be expensive as it requires isotopic labelled proteins and is limited by protein molecular weight (Kay and Gardner, 1997), and although SAXS can provide information on the overall shape of the protein, it is a low-resolution technique and its measurement is prone to interferences from aggregation and heterogeneity (Kikhney and Svergun, 2015). Hence, we tend to integrate these different approaches to tease out the complex interplay between structure and dynamics and get a more complete picture of the enzyme system.

Case study 1: What is the role of *Mtb* ICL isoform 2?

One of the first questions that we asked when we started to study *Mtb* carbon metabolism was why *Mtb* has two isoforms of ICL. What makes this particularly perplexing was conflicting

published observations between cell-based experiments implicating ICL1 and ICL2 in *Mtb's* virulence and survival, whilst *in vitro* assays reported recombinant *Mtb* ICL2 as unstable and inactive/barely active (Höner zu Bentrup et al., 1999; Gould et al., 2006). Given that *Mtb* thrives in nutrient-limited environments, we hypothesised that it would be unlikely for the bacterium to invest its limited resources in producing a protein or enzyme that serves no function. Hence, we decided ICL2 was worth further detailed investigation (see Bhusal et al., 2019 for full paper).

When we first started working on *Mtb* ICL2, in the time pre-Alphafold, there was no structural information available for the protein, so we began by examining its sequence and structure. Comparing the protein sequence of *Mtb* ICL2 with *Mtb* ICL1, we identified two large inserts in ICL2. The first, which is located in the protein core, resembles an insert commonly found in fungal ICLs. Interestingly, however, the second insert, which is located at the C-terminus, had no sequence similarity to any known proteins. Since bioinformatics (e.g., BLAST sequence searching) provided no additional insights, we decided to pursue X-ray crystallography experiments to solve its structure.

This enabled us to obtain the apo-structure of ICL2 (PDB: 6EDW), revealing that the protein exists as a tetramer (Figure 4a). The structure of the monomer showed that ICL2 consists of two distinct domains connected by a flexible linker. As we predicted, the N-terminal domain is structurally similar to fungal ICLs and contains the active site. In the tetrameric structure, we found the four N-terminal domains assemble into a core arrangement, which is consistent with other ICLs. In contrast, the unique C-terminal domains interacted in pairs to form dimers. This resulted in an elongated overall structure of the ICL2 protein.

Using bioinformatics tools that compare protein crystal structures (Krissinel and Henrick, 2004; Tung et al., 2007; Yang and Tung, 2006), we then searched for proteins that share structural similarity with the *Mtb* ICL2 C-terminal domain. Surprisingly, the C-terminal domain was

found to be similar to a family of enzymes called Gcn5-related N-acetyltransferases (GNATs) (Favrot et al., 2016). This discovery led us to investigate whether compounds such as acetyl-CoA might interact with ICL2. To test this, we studied the enzyme kinetics of ICL2 with and without acetyl-CoA by using ^{1}H NMR spectroscopy. We chose NMR given we were unsure about the specific chemical reactions that ICL2 might catalyse. Considering the acetyltransferase activity common among GNATs, we were unsure whether the C-terminal domain might act as an acetyltransferase to modify ICL2 itself or other substrates such as isocitrate. Conducting a time-course experiment with ICL2, isocitrate, acetyl-CoA and Mg^{2+} we observed a significant increase in isocitrate turnover when acetyl-CoA was present, but not in the reaction without acetyl-CoA (Figure 4b). Notably, there was also no detectable turnover of acetyl-CoA to CoA, indicating that the C-terminal domain does not act as an acetyltransferase. Together, these findings suggest that acetyl-CoA likely binds to ICL2 at the C-terminal domain and activates the enzyme.

To investigate this further, we returned to crystallography and successfully obtained a crystal structure of ICL2 bound to acetyl-CoA (PDB: 6EE1). The structure revealed that the C-terminal domain serves as the binding site for acetyl-CoA and showed a significant conformational change in the ICL2 protein. Specifically, the two C-terminal domain dimers dissociated and re-formed as dimers with the other C-terminal domains (Figure 4a). To confirm this unexpected observation, we turned to a solution-based technique to validate this finding. However, given the size of the tetrameric protein, methods such as protein NMR spectroscopy were not suitable. Instead, we opted for SAXS (Schneidman-Duhovny and Hammel, 2018). Our SAXS results were consistent with the crystal structure, confirming that acetyl-CoA binding induces a significant conformational change in the enzyme in solution. Finally, we also engaged with our colleagues in computational chemistry, in which we applied molecular dynamics simulations to validate our experimental results (Jiao and Parker, 2012).

This case study highlights our approach in leveraging different complementary techniques to solve biological problems. It demonstrates the power of combining structural tools such as X-ray crystallography, bioinformatics (e.g., structural similarity searches), and kinetic assays to elucidate enzyme function. We also demonstrate how methods like ^{1}H NMR spectroscopy, though slower to perform, can provide a wealth of information than "faster" experiments such as spectrophotometry-based activity assays, as NMR enabled us to determine whether the protein functions as an acetyltransferase and how acetyl-CoA modulates ICL activity in a single experiment.

Our findings also provided exciting biological insight, as we revealed that ICL2 is allosterically regulated by acetyl-CoA. This is a significant discovery because acetyl-CoA is produced in higher concentrations during β-oxidation compared to glycolysis. These results suggest a potential link between *Mtb's* carbon substrate utilisation and metabolic pathway activation. They also highlight the role of ICL2 as a gatekeeper of *Mtb's* glyoxylate shunt. Hence, this case study is a prime example of how a comprehensive structural enzymology investigation can provide biologically relevant information on the enzyme as well as the pathway that it is involved in and how it impacts the interaction of an organism with its environment.

<INSERT FIGURE 4 HERE>

Figure 4: Elucidating the structure and mechanism of Mtb ICL2: *(a) Crystallography studies led to the elucidation of Mtb ICL2 structure in its apo (PDB: 6EDW) and acetyl-CoA-bound (PDB: 6EE1) forms; (b) These structures revealed an allosteric mechanism that activates the enzyme, which is triggered by the binding of acetyl-CoA at the C-terminal domain. The reaction mixture contained 500 nM ICL2, 25 µM acetyl-CoA (where applicable), 1 mM DL-isocitrate, 5 mM MgCl$_2$, 0.02% NaN$_3$, 50 mM Tris-d$_{11}$ (pH 7.5) in 90% H$_2$O and 10% D$_2$O. Error bars represent standard deviation from three replicates. The data was collected using a 700 MHz Bruker Avance IIIHD spectrometer with TCI cryoprobe.*

Case study 2: How does itaconate, a host metabolite, target *Mtb* ICL?

Since the glyoxylate shunt is essential for the survival and persistence of *Mtb* within the infected host, it is not surprising that the immune system has developed strategies to target this

pathway. One of the most famous examples is itaconate, an antimicrobial metabolite produced by the macrophage (Cordes et al., 2015; O'Neill & Artyomov, 2019) (Figure 5a). Although itaconate is known to be an inhibitor of ICL (McFadden and Purohit, 1977; Rao and McFadden, 1965; Rittenhouse and McFadden, 1974), its mode of action has never been reported. As chemists, when we first examined the structure of itaconate, we were struck by the presence of the α,β-unsaturated carbonyl group, which suggests it could be prone to nucleophilic attack by acting as a Michael acceptor (Jackson et al., 2017) (Figure 5a). Given that the *Mtb* ICL active site contains a nucleophilic cysteine residue (Moynihan and Murkin, 2014), this observation led us to investigate whether itaconate functions as a covalent inhibitor of *Mtb* ICL1 and ICL2 (see Kwai et al., 2021 for full paper).

We first conducted intact protein analysis under denaturing conditions to study recombinant *Mtb* ICL1 that was incubated with itaconate (and Mg^{2+}, which is required for ICL activity). We started with this approach as it can act as a "fast fail" experiment by providing a quick and definitive answer as to whether itaconate could covalently modify *Mtb* ICL1. A comparison of the mass spectrum of ICL1 with that of ICL1 incubated with itaconate and Mg^{2+} revealed a mass increase of 130 Da, which corresponds to the covalent addition of an itaconate molecule to the protein (Figure 5b). As a control, incubation of itaconate and Mg^{2+} with an ICL1 mutant in which the catalytic cysteine was replaced with serine showed no mass shift. This indicates that a nucleophile is needed for the covalent reaction. This was further confirmed by tandem mass spectrometry with trypsin digestion, which pinpointed the site of modification to the active site cysteine residue. Finally, to verify the modification site on itaconate, we crystallised the itaconate-modified *Mtb* ICL1 (Figure 5c). The structure revealed that the cysteine residue attacked the terminal carbon of the alkene moiety in itaconate to form a 2-methylsuccinate adduct, which is consistent with the proposed 1,4-conjugate addition reaction mechanism (Figure 4a).

We then conducted kinetic analysis to monitor covalent adduct formation by intact protein mass spectrometry. Under our initial incubation condition with only ICL1, itaconate and Mg^{2+}, our data revealed that covalent adduct formation was quite slow; full conversion of ICL1 into the covalent itaconate adduct was only achieved after 5 hours of incubation. We were not satisfied with this finding because this prolonged reaction time would have suggested that covalent adduct formation is unlikely to be biologically relevant. We therefore re-examined our reaction conditions. Structurally, itaconate is an analogue of succinate, which is one of the reaction products (along with glyoxylate) when isocitrate is used as a substrate. Hence, in the absence of glyoxylate, itaconate might not bind optimally to ICL. This led us to hypothesise that the presence of glyoxylate might accelerate the formation of the ICL1-itaconate covalent adduct. Indeed, we found that in the presence of glyoxylate, itaconate, and Mg^{2+}, the covalent reaction with ICL1 occurred almost instantaneously. This finding not only demonstrates that the reaction can occur on a biologically relevant timescale but also provides insights into how itaconate/succinate and glyoxylate might interact at the enzyme's active site.

This is another example that highlights our integrated approach to enzyme research. It shows how chemical and biochemical intuitions can not only initiate but also guide a project to completion. We used whole protein mass spectrometry as a "fast fail" experiment at the beginning of this project. Not only it acted as a screening tool, but it was also definitive. By performing "fast fail" experiments first and then increase complexity later, it helps to prevent investing time and resources into systems that do not show positive results. In addition, as with the first case study, it demonstrates how combining different techniques – in this case, mass spectrometry, X-ray crystallography, and mutagenesis studies – can clarify the inhibition mechanism of a natural antibiotic agent and improve our understanding of the interactions and warfare between *Mtb* and its human host.

<INSERT FIGURE 5 HERE>

Figure 5: Combined approach using mass spectrometry and X-ray crystallography to identifying itaconate is a covalent inhibitor of Mtb ICL1. (a) The structure of itaconate, which contains an α,β-unsaturated carbonyl group, led us to propose that it might react covalently with the active site cysteine of ICL via a 1,4-conjugate addition mechanism.; (b) Intact protein analysis under denaturing condition showed that itaconate forms a covalent adduct with Mtb ICL1. This experiment acted as a fast fail test before proceeding to further analyses; (c) Crystal structure of the ICL1-itaconate adduct showed the modification site on itaconate, which confirms the proposed reaction mechanism. Figure 4b and 4c were modified and reprinted with permission from Kwai et al., 2021.

Case study 3: Rv1916, a protein resulted from splicing of the ICL2 gene

In *Mtb* H37Rv, the most commonly used *Mtb* laboratory strain, the gene that encodes ICL2 is split into two reading frames, *rv1915* (*aceAa*) and *rv1916* (*aceAb*), due to a frameshift mutation that results in a premature stop codon (Fleischmann et al., 2002) (Figure 6a). Initially, both *rv1915* and *rv1916* were characterised as pseudogenes (Höner Zu Bentrup et al., 1999). Subsequent computational analyses suggested that Rv1916 (the protein that encoded by *rv1916*) might be involved in the synthesis of secondary metabolites (Antil et al., 2019). Follow-up studies from the same group indicated that Rv1916 may even possess ICL activity (Antil et al., 2019, Antil et al., 2022). We were intrigued by this reported ICL activity as Rv1916 lacks the conserved KKCGH motif at the active site that is essential for ICL function (Figure 6a). We therefore decided to investigate this further (see Huang et al., 2023 for full paper).

We first expressed Rv1916 recombinantly and confirmed the protein was properly folded using CD spectroscopy, to characterise its secondary structure. This acted as a "fast fail" test as it was possible that Rv1916 was produced as an unstructured protein. We then tested its activity using ^{1}H NMR. We chose to use NMR as our detection method as opposed to spectrophotometry measurements (such as those that were used by the original authors) because absorbance is less sensitive at low product concentrations, and we also wanted to use a technique that will allow us to more conclusively tell whether there is turnover of the substrates at all. Contrary to the published reports (Antil et al., 2019, Antil et al., 2022), our results showed no turnover of isocitrate, either with or without acetyl-CoA, when incubated with Rv1916 and Mg^{2+}. As these

results conflicted with the literature, we decided to crystallise Rv1916 so that we could obtain structural evidence to validate or explain our findings.

The crystal structure revealed that Rv1916 is structurally identical to the C-terminal domain of ICL2, which is known to bind acetyl-CoA (Figure 6b). It also contains no structural similarities to the active site of any known ICL enzymes. We therefore next tested whether Rv1916 could bind acetyl-CoA as a ligand. As acetyl-CoA activates ICL2 in the µM concentration, we needed to use a binding technique that would allow us to measure protein-ligand interactions in the µM to mM affinity range. We therefore decided to use waterLOGSY (water-ligand observed via gradient spectroscopy), an NMR-based technique that is commonly used in fragment-based drug discovery and is suitable for the affinity range (Huang et al., 2017; Huang and Leung, 2019). Using this method, we confirmed that Rv1916 is indeed an acetyl-CoA binding protein (Figure 6c). Moreover, we observed no binding interaction between Rv1916 and isocitrate, which further supports our observation that Rv1916 is not an isocitrate lyase enzyme.

This example further underscores the importance of selecting the appropriate techniques for measurements and employing complementary methods to validate unexpected findings. By prioritising techniques that provide more definitive answers, such as X-ray crystallography for structural determination (rather than computational modelling), biophysical binding experiments (instead of docking), and detailed kinetic studies (over spectrophotometry), we resolved discrepancies in the literature and ruled out several proposed roles and functions for the protein. While we were unable to determine the biological function of Rv1916, our work corrected its previously misassigned role and definitively demonstrated that it does not possess ICL activity.

<INSERT FIGURE 6 HERE>

Figure 6: Combined approach using NMR-based binding experiments and X-ray crystallography to show Rv1916 as an acetyl-CoA binding protein. *(a) Schematic comparison of Mtb ICL2 with Rv1915 and Rv1916. The N-terminal domain of ICL2 is*

highlighted in pink. The ICL2 C-terminal domain is highlighted in yellow, and the ICL2 flexible linker connecting the two domains is highlighted in blue. The domain highlighted in red in Rv1915 differs from ICL2 due to the frameshift mutation. The conserved KKCGH domain is missing in Rv1916; (b) Crystal structure of Rv1916$_{233-398}$ (PDB: 8G8K; blue) showed good overlap with the C-terminal domain (green) of full-length ICL2 (PDB: 6EDW); (c) WaterLOGSY spectrum of acetyl-CoA in the presence (red) and absence (blue) of Rv1916. Hash (#) indicates Tris peak and asterisks (*) indicate acetyl-CoA peaks. The data shows that acetyl-CoA is a ligand of Rv1916 as the non-exchangeable proton signals of acetyl-CoA turned from negative to positive upon the addition of the protein. Figure 5a, 5b and 5c were modified and reprinted with permission from Huang et al. 2023.

Outlook: Further broadening our approach to studying *Mtb* carbon metabolism

Through the case studies and examples above, we have detailed the effectiveness of our integrated approach in using complementary techniques to tackle biological problems. We highlighted the value of employing information-rich techniques early in a project, allowing them to act as "fast fail" tests to guide subsequent steps. We also emphasised the importance of analysing structures as well as the importance to combine structural knowledge along with the underlying chemistry to inform project development and experiment planning. Finally, we showed how addressing biological questions from multiple angles and perspectives, such as structurally and mechanistically, may help to generate robust data that not only supports *in vitro* enzymology research but also provides deeper insights into the biological problems at hand.

As we deepen our understanding of the enzymology behind the key regulators at this critical metabolic node in *Mtb* carbon metabolism, new questions continue to emerge. Several studies from other research groups have highlighted potential cross-pathway interactions at this metabolic junction. For instance, glyoxylate from the glyoxylate shunt has been shown to cross-activate ICD2 in the TCA cycle (Murima et al., 2016). Moreover, there is growing evidence suggesting potential post-translational regulation of the *Mtb* ICL and ICD enzymes as they were found to be posttranslationally acetylated in several studies (Bi et al., 2017; Birhanu et al., 2017; Lee et al., 2017; Zhou et al., 2017). For example, Lee et al. (2017) demonstrated that ICD1 might be negatively regulated by post-translational lysine acetylation. These findings add

another layer of complexity in the regulation of this important metabolic node and its intricacy remains to be fully elucidated.

Looking ahead, to fully understand the regulation of *Mtb* carbon metabolism and its impact on the bacterium's survival and virulence in its host, it is crucial to expand our integrated approach beyond *in vitro* activity assays, biophysics and structural biology. Thus far, our work has been conducted entirely *in vitro*. This underscores the need to integrate these data with cell-based studies. For example, metabolomics experiments to explore metabolic changes in *Mtb* under different growth conditions (e.g., different carbon sources) could provide expansive datasets that could be correlated with findings from our in vitro experiments. We could also expand this further into multi-omics analyses by incorporating lipidomics, transcriptomics, and proteomics, which could provide a more comprehensive view of *Mtb* metabolism and enable us to link enzyme function to broader shifts in metabolic flux under varying conditions. More interestingly, the combination of flux predictions and modelling (e.g., based on metabolomics data) and proteomics data (for protein quantification) have been shown to allow the determination of enzyme kinetics *in vivo*, which would be highly valuable in understanding the physiological roles of these enzymes in different conditions (Davidi et al., 2016; Heckmann et al., 2020; Wright et al., 1992). Finally, validating these findings in cellular contexts will be essential to bridge the gap between biochemistry and host-pathogen interactions. Hence, experiments using macrophage infection models or similar systems would ensure that our findings are relevant to the complex and fluctuating environment that *Mtb* resides in. These combined analyses will bring us closer to uncovering the metabolic strategies that enable its persistence within the host.

Overall, in this perspective, we highlighted the multi-layered benefits of our integration of biochemical, structural and mechanistic approaches to build a comprehensive picture of how key enzymes like ICL and ICD function at the intersection of the TCA cycle and the glyoxylate

shunt. We hope that aspects of our approach will provide useful guidance for readers as they design new projects to investigate the function and regulation of other biochemical pathways and inspire others to further explore this important field of *Mtb* metabolism.

Conflicts of interest

All authors declare that they have no conflicts of interest to disclose.

References

Ahmad F, Rani A, Alam A, Zarin S, Pandey S, Singh H, Hasnain SE and Ehtesham NZ (2022) Macrophage: a cell with many faces and functions in tuberculosis. *Frontiers in Immunology* **13**, 747799.

Akram M (2014) Citric acid cycle and role of its intermediates in metabolism. *Cell Biochemistry and Biophysics* **68**, 475–478.

Antil M and Gupta V (2022) Rv1915 and Rv1916 from *Mycobacterium tuberculosis* H37Rv form in vitro protein-protein complex. *Biochimica et Biophysica Acta – General Subjects* **1866**, 130130.

Antil M, Sharma J, Brissonnet Y, Choudhary M, Gouin S and Gupta V (2019) Structure-function insights into elusive *Mycobacterium tuberculosis* protein Rv1916. *International Journal of Biological Macromolecules* **141**, 927–936.

Appelberg R (2006) Macrophage nutriprive antimicrobial mechanisms. *Journal of Leukocyte Biology* **79**, 1117–1128.

Asor R and Kukura P (2022) Characterising biomolecular interactions and dynamics with mass photometry. *Current Opinion in Chemical Biology* **68**, 102132.

Banerjee S, Nandyala A, Podili R, Katoch VM and Hasnain SE (2005) Comparison of *Mycobacterium tuberculosis* isocitrate dehydrogenases (ICD-1 and ICD-2) reveals differences in coenzyme affinity, oligomeric state, pH tolerance and phylogenetic affiliation. *BMC Biochemistry* **6**, 20.

Bastos M, Abian O, Johnson CM, Ferreira-da-Silva F, Vega S, Jimenez-Alesanco A, Ortega-Alarcon D and Velazquez-Campoy A (2023) Isothermal titration calorimetry. *Nature Reviews Methods Primers* **3**, 17.

Bhusal RP, Bashiri G, Kwai BXC, Sperry J and Leung IKH (2017a) Targeting isocitrate lyase for the treatment of latent tuberculosis. *Drug Discovery Today* **22**, 1008–1016.

Bhusal RP, Jiao W, Kwai BXC, Reynisson J, Collins AJ, Sperry J, Bashiri G and Leung IKH (2019) Acetyl-CoA-mediated activation of *Mycobacterium tuberculosis* isocitrate lyase 2. *Nature Communications* **2019**, 10, 4639.

Bhusal RP, Patel K, Kwai BXC, Swartjes A, Bashiri G, Reynisson J, Sperry J and Leung IKH (2017b) Development of NMR and thermal shift assays for the evaluation of *Mycobacterium tuberculosis* isocitrate lyase inhibitors. *Medicinal Chemistry Communications* **8**, 2155–2163

Bi J, Wang Y, Yu H, Qian X, Wang H, Liu J and Zhang X (2017) Modulation of central carbon metabolism by acetylation of isocitrate lyase in *Mycobacterium tuberculosis*. *Scientific Reports* **7**, 44826.

Birhanu AG, Yimer SA, Holm-Hansen C, Norheim G, Aseffa A, Abebe M and Tønjum T (2017) Nε- and O-acetylation in *Mycobacterium tuberculosis* lineage 7 and lineage 4 strains: proteins

involved in bioenergetics, virulence, and antimicrobial resistance are acetylated. *Journal of Proteome Research* **16**, 4045–4059.

Boehr DD, Dyson HJ and Wright PE (2006) An NMR perspective on enzyme dynamics. *Chemical Reviews* **106**, 3055–3079.

Borah K, Mendum TA, Hawkins ND, Ward JL, Beale MH, Larrouy-Maumus G, Bhatt A, Moulin M, Haertlein M, Strohmeier G, Pichler H, Forsyth VT, Noack S, Goulding CW, McFadden J and Beste DJV (2021) Metabolic fluxes for nutritional flexibility of *Mycobacterium tuberculosis*. *Molecular Systems Biology* **17**, e10280.

Celej MS, Montich GG and Fidelio GD (2003) Protein stability induced by ligand binding correlates with changes in protein flexibility. *Protein Science* **12**, 1496–1506.

Chang DPS and Guan XL (2021) Metabolic versatility of *Mycobacterium tuberculosis* during infection and dormancy. *Metabolites* **11**, 88.

Chubukov V, Gerosa L, Kochanowski K and Sauer U (2014) Coordination of microbial metabolism. *Nature Reviews Microbiology* **12**, 327–340.

Compton PD, Zamdborg L, Thomas PM and Kelleher NL (2011) On the scalability and requirements of whole protein mass spectrometry. *Analytical Chemistry* **83**, 6868–6874.

Cordes T, Michelucci A and Hiller K (2015) Itaconic acid: the surprising role of an industrial compound as a mammalian antimicrobial metabolite. *Annual Review of Nutrition* **35**, 451–473.

Cottrell JS (2011) Protein identification using MS/MS data. *Journal of Proteomics* **74**, 1842–1851.

Davidi D, Noor E, Liebermeister W, Bar-Even A, Flamholz A, Tummler K, Barenholz U, Goldenfeld M, Shlomi T and Milo R (2016) Global characterization of *in vivo* enzyme catalytic

rates and their correspondence to *in vitro* kcat measurements. *Proceedings of the National Academy of Sciences of the United States of America* **113**, 3401–3406.

De Boer AR, Letzel T, van Elswijk DA, Lingerman H, Niessen WMA and Irth H (2004) On-line coupling of high-performance liquid chromatography to a continuous-flow enzyme assay based on electrospray ionization mass spectrometry. *Analytical Chemistry* **76**, 3155–3161.

De Carvalho LPS, Fischer SM, Marrero J, Nathan C, Ehrt S and Rhee KY (2010) Metabolomics of *Mycobacterium tuberculosis* reveals compartmentalized co-catabolism of carbon substrates. *Chemistry & Biology* **17**, 1122–1131.

Desvergne B, Michalik L and Wahli W (2006) Transcriptional regulation of metabolism. *Physiological Reviews* **86**, 465–514.

Dixon GH and Kornberg HL (1959) Assay methods for key enzymes of the glyoxylate cycle. *Proceedings of the Biochemical Society* **72**, 3p.

Dobson CM (2019) Biophysical techniques in structural biology. *Annual Review of Biochemistry* **88**, 25–33.

Dobson RCJ and Patel TR (2020) Analytical ultracentrifugation: still the gold standard that offers multiple solutions. *European Biophysics Journal* **49**, 673–676.

Dolan SK and Welch M (2018) The glyoxylate shunt, 60 years on. *Annual Review of Microbiology* **72**, 309–330.

Ehrt S, Schnappinger D and Rhee KY (2018) Metabolic principles of persistence and pathogenicity in *Mycobacterium tuberculosis*. *Nature Reviews Microbiology* **16**, 496–507.

El-Aneed A, Cohen A and Banoub J (2009) Mass spectrometry, review of the basics: electrospray, MALDI, and commonly used mass analyzers. *Applied Spectroscopy Reviews* **44**, 210–230.

Eoh H and Rhee KY (2013) Multifunctional essentiality of succinate metabolism in adaptation to hypoxia in *Mycobacterium tuberculosis*. *Proceedings of the National Academy of Sciences* **110**, 6554–6559.

Favrot L, Blanchard JS and Vergnolle O (2016) Bacterial GCN5-related N-acetyltransferases: from resistance to regulation. *Biochemistry* **55**, 989–1002.

Fleischmann RD, Alland D, Eisen JA, Carpenter L, White O, Peterson J, DeBoy R, Dodson R, Gwinn M, Haft D, Hickey E, Kolonay JF, Nelson WC, Umayam LA, Ermolaeva M, Salzberg SL, Delcher A, Utterback T, Weidman J, Khouri H, Gill J, Mikula A, Bishai W, Jacobs Jr WR, Venter JC and Fraser CM (2022) Whole-genome comparison of *Mycobacterium tuberculosis* clinical and laboratory strains. *Journal of Bacteriology* **184**, 5479–5490.

Galland S, Le Borgne F, Guyonnet D, Clouet P and Demarquoy J (1998) Purification and characterization of the rat liver gamma-butyrobetaine hydroxylase. *Molecular and Cellular Biochemistry* **178**, 163–168.

Gomez JE and McKinney JD (2004) M. tuberculosis persistence, latency, and drug tolerance. *Tuberculosis* **84**, 29–44.

Gould TA, Van De Langemheen H, Muñoz-Elías EJ, McKinney JD and Sacchettini JC (2006) Dual role of isocitrate lyase 1 in the glyoxylate and methylcitrate cycles in *Mycobacterium tuberculosis*. *Molecular Microbiology* **61**, 940–947.

Greis KD (2007) Mass spectrometry for enzyme assays and inhibitor screening: an emerging application in pharmaceutical research. *Mass Spectrometry Reviews* **26**, 324–339.

Heckmann D, Campeau A, Lloyd CJ, Phaneuf PV, Hefner Y, Carrillo-Terrazas M, Feist AM, Gonzalez DJ and Palsson BO (2020) Kinetic profiling of metabolic specialists demonstrates stability and consistency of *in vivo* enzyme turnover numbers. *Proceedings of the National Academy of Sciences of the United States of America* **117**, 23182–23190.

Höner Zu Bentrup K, Miczak A, Swenson DL and Russell DG (1999) Characterization of activity and expression of isocitrate lyase in *Mycobacterium avium* and *Mycobacterium tuberculosis*. *Journal of Bacteriology* **181**, 7161–7167.

Howlett GJ, Minton AP and Rivas G (2006) Analytical ultracentrifugation for the study of protein association and assembly. *Current Opinion in Chemical Biology* **10**, 430–436.

Huang EYW, Kwai BXC, Bhusal RP, Bashiri G and Leung IKH (2023) *Mycobacterium tuberculosis* Rv1916 is an acetyl-CoA-binding protein. *ChemBioChem* **24**, e202300162.

Huang R, Bonnichon A, Claridge TDW and Leung IKH (2017) Protein-ligand binding affinity determination by the waterLOGSY method: an optimised approach considering ligand rebinding. *Scientific Reports* **7**, 43727.

Huang R and Leung IKH (2019) Protein-small molecule interactions by waterLOGSY. *Methods in Enzymology* **615**, 477–500.

Huynh K and Partch CL (2015) Analysis of protein stability and ligand interactions by thermal shift assay. *Current Protocols in Protein Science* **79**, 28.9.1–28.9.14.

Ishima R and Torchia DA (2000) Protein dynamics from NMR. *Nature Structural Biology* **7**, 740–743.

Jackson PA, Widen JC, Harki DA and Brummond KM (2017) Covalent modifiers: a chemical perspective on the reactivity of α,β-unsaturated carbonyls with thiols via hetero-Michael addition reactions. *Journal of Medicinal Chemistry* **60**, 839–885.

Jiao W and Parker EJ (2012) Using a combination of computational and experimental techniques to understand the molecular basis for protein allostery. *Advances in Protein Chemistry and Structural Biology* **87**, 391–413.

Kay LE and Gardner KH (1997) Solution NMR spectroscopy beyond 25 kDa. *Current Opinion in Structural Biology* **7**, 722–731.

Kikhney AG and Svergun DI (2015) A practical guide to small angle X-ray scattering (SAXS) of flexible and intrinsically disordered proteins. *FEBS Letter* **589**, 2570–2577.

Krimm I (2017). Applications of ligand and protein-observed NMR in ligand discovery. In Applied Biophysics for Drug Discovery, (eds. D Huddler and ER Zartler), pp. 175-195. Chichester: John Wiley & Sons.

Krissinel E and Henrick K (2004) Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. *Acta Crystallographica Section D: Structural Biology* **60**, 2256–2268.

Kwai BXC, Collins AJ, Middleditch MJ, Sperry J, Bashiri G and Leung IKH (2021) Itaconate is a covalent inhibitor of the *Mycobacterium tuberculosis* isocitrate lyase. *RSC Medicinal Chemistry* **12**, 57–61.

Laval T, Chaumont L and Demangel C (2021) Not too fat to fight: the emerging role of macrophage fatty acid metabolism in immunity to *Mycobacterium tuberculosis*. *Immunological Review* **301**, 84–97.

Lee W, VanderVen BC, Walker S and Russell DG (2017) Novel protein acetyltransferase, Rv2170, modulates carbon and energy metabolism in *Mycobacterium tuberculosis*. *Scientific Reports* **7**, 72.

Leung E; Patel J, Hollywood JA, Zafar A, Tomek P, Barker D, Pilkington LI, van Rensburg M, Langley RJ, Helsby NA, Squire CJ, Baguley BC, Denny WA, Reynisson J and Leung IKH (2021) Validating TDP1 as an inhibition target for the development of chemosensitizers for camptothecin-based chemotherapy drugs. *Oncology and Therapy* **9**, 541–556.

Leung IKH, Krojer TJ, Kochan GT, Henry L, von Delft F, Claridge TDW, Oppermann U, McDonough MA and Schofield CJ (2010) Structural and mechanistic studies on γ-butyrobetaine hydroxylase. *Chemistry & Biology* **17**, 1316–1324.

Locasale JW (2018) New concepts in feedback regulation of glucose metabolism. *Current Opinion in Systems Biology* **8**, 32–28.

Long CP and Antoniewicz MR (2014) Metabolic flux analysis of *Escherichia coli* knockouts: lessons from the Keio collection and future outlook. *Current Opinion in Biotechnology* **28**, 127–133.

Maksymiuk C, Balakrishnan A, Bryk R, Rhee KY and Nathan CF (2015) E1 of α-ketoglutarate dehydrogenase defends *Mycobacterium tuberculosis* against glutamate anaplerosis and nitroxidative stress. *Proceedings of the National Academy of Sciences of the United States of America* **112**, E5834–E5843.

Marrero J, Rhee KY, Schnappinger D, Pethe K and Ehrt S (2010) Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for *Mycobacterium tuberculosis* to establish and maintain infection. *Proceedings of the National Academy of Sciences of the United States of America* **107**, 9819–9824.

Mashabela GT, de Wet TJ, Warner DF (2019) *Mycobacterium tuberculosis* metabolism. *Microbiology Spectrum* **7**..

Mbenza NM, Vadakkedath PG, McGillivray DJ and Leung IKH (2017) NMR studies of the non-haem Fe(II) and 2-oxoglutarate-dependent oxygenases. *Journal of Inorganic Biochemistry* **177**, 384–394.

McFadden BA and Purohit S (1977) Itaconate, an isocitrate lyase-directed inhibitor in Pseudomonas Indigofera. *Journal of Bacteriology* **131**, 136–144.

McKinney JD, Höner zu Bentrup K, Muñoz-Elías EJ, Miczak A, Chen B, Chan WT, Swenson D, Sacchettini JC, Jacobs Jr WR, and Russell DG (2000) Persistence of *Mycobacterium tuberculosis* in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. *Nature* **406**, 735–738.

Miles AJ, Janes RW and Wallace BA (2021) Tools and methods for circular dichroism spectroscopy of proteins: a tutorial review. *Chemical Society Reviews* **50**, 8400–8413.

Moynihan MM and Murkin AS (2013) Cysteine is the general base that serves in catalysis by isocitrate lyase and in mechanism-based inhibition by 3-nitropropionate. *Biochemistry* **53**, 178–187.

Muñoz-Elías EJ and McKinney JD (2005) *Mycobacterium tuberculosis* isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. *Nature Medicine* **11**, 638–644.

Muñoz-Elías EJ, Upton AM, Cherian J and McKinney JD (2006) Role of the methylcitrate cycle in *Mycobacterium tuberculosis* metabolism, intracellular growth, and virulence. *Molecular Microbiology* **60**, 1109–1122.

Murima P, Zimmermann M, Chopra T, Pojer F, Fonti G, Dal Peraro M, Alonso S, Sauer U, Pethe K and McKinney JD (2016) A rheostat mechanism governs the bifurcation of carbon flux in mycobacteria. *Nature Communications* **7**, 12527.

Nachlas MM, Davidson MB, Goldberg JD and Seligman AM (1963) Colorimetric method for the measurement of isocitric dehydrogenase activity. *Journal of Laboratory and Clinical Medicine* **62**, 148–158.

Nakayama GR (1998) Microplate assays for high-throughput screening. *Current Opinion in Drug Discovery and Development* **1**, 85–91.

Nandakumar M, Nathan C, and Rhee KY (2014) Isocitrate lyase mediates broad antibiotic tolerance in *Mycobacterium tuberculosis*. *Nature Communications* **5**, 4306.

Nielsen J (2017) Systems biology of metabolism. *Annual Review of Biochemistry* **86**, 245–275.

O'Neill LAJ and Artyomov MN (2019) Itaconate: the poster child of metabolic reprogramming in macrophage function. *Nature Reviews Immunology* **19**, 273–281.

Park JH, Shim D, Kim KES, Lee W and Shin SJ (2021) Understanding metabolic regulation between host and pathogens: new opportunities for the development of improved therapeutic strategies against *Mycobacterium tuberculosis* infection. *Frontiers in Cellular and Infection Microbiology* **11**, 635335.

Pattnaik P (2005) Surface plasmon resonance. Applications in understanding receptor-ligand interaction. *Applied Biochemistry and Biotechnology* **126**, 79–92.

Rao GR and McFadden BA (1965) Isocitrate lyase from Pseudomonas indigofera: IV. Specificity and inhibition. *Archives of Biochemistry and Biophysics* **112**, 294–303.

Renaud JP, Chari A, Ciferri C, Liu WT, Rémigy HW, Stark H and Wiesmann C (2018) Cryo-EM in drug discovery: achievements, limitations and prospects. *Nature Reviews Drug Discovery* **17**, 471–492.

Rhee KY, de Carvalho LPS, Bryk R, Ehrt S, Marrero J, Park SW, Schnappinger D, Venugopal A and Nathan C (2011) Central carbon metabolism in *Mycobacterium tuberculosis*: an unexpected frontier. *Trends in Microbiology* **19**, 307–314.

Rittenhouse JW and McFadden BA (1974) Inhibition of isocitrate lyase from Pseudomonas indigofera by itaconate. *Archives of Biochemistry and Biophysics* **163**, 79–86.

Rodriguez GM, Sharma N, Biswas A and Sharma N (2022) The iron response of *Mycobacterium tuberculosis* and its implications for tuberculosis pathogenesis and novel therapeutics. *Frontiers in Cellular and Infection Microbiology* **12**, 876667.

Rokosh DA, Kurz WGW and LaRue TA (1973) A modification of isocitrate and malate dehydrogenase assays for use in crude cell free extracts. *Analytical Biochemistry* **54**, 477–483.

Russell DG, VanderVen BC, Lee W, Abramovitch RB, Kim MJ, Homolka S, Niemann S and Rohde KH (2010) *Mycobacterium tuberculosis* wears what it eats. *Cell Host & Microbe* **8**, 68–76.

Saelens JW, Viswanathan G and Tobin DM (2019) Mycobacterial evolution intersects with host-tolerance. *Frontiers in Immunology* **10**, 528.

Santiveri CM, López-Méndez B, Huecas S, Alfonso C, Luque-Ortega JR and Campos-Olivas R (2017) A biophysical toolkit for molecular interactions. In eLS. Chichester: John Wiley & Sons.

Serafini A, Tan L, Horswell S, Howell S, Greenwood DJ, Hunt DM, Phan MD, Schembri M, Monteleone M, Montague CR, Britton W, Garza-Garcia A, Snijders AP, VanderVen B, Gutierrez MG, West NP and de Carvalho LPS (2019) *Mycobacterium tuberculosis* requires glyoxylate shunt and reverse methylcitrate cycle for lactate and pyruvate metabolism. *Molecular Microbiology* **112**, 1284–1307.

Schneidman-Duhovny D and Hammel M (2018) Modeling structure and dynamics of protein complexes with SAXS profiles. *Methods in Molecular Biology* **1764**, 449–473.

Sharma N, Langley RJ, Eurtivong C, Leung E, Dixon RJ, Paulin EK, Rees SWP, Pilkington LI, Barker D, Reynisson J and Leung IKH (2021) An optimised MALDI-TOF assay for phosphatidylcholine-specific phospholipase C. *Analytical Methods* **13**, 491–496.

Shoemaker SC and Ando N (2018) X-rays in the cryo-EM era: structural biology's dynamic future. *Biochemistry* **57**, 277–285.

Simkhovich BZ, Shutenko ZV, Meirēna DV, Khagi KB, Mežapuķe RJ, Molodchina TN, Kalvlņš IJ and Lukevics E (1988) 3-(2,2,2-Trimethylhydrazinium)propionate(THP)–a novel γ-

butyrobetaine hydroxylase inhibitor with cardioprotective properties. *Biochemical Pharmacology* **37**, 195–202.

Sittampalam GS, Kahl SD and Janzen WP (1997) High-throughput screening: advances in assay technologies. *Current Opinion in Chemical Biology* **1**, 384–391.

Spaniol M, Brooks H, Auer L, Zimmermann A, Solioz M, Stieger B and Krähenbühl S (2001) Development and characterization of an animal model of carnitine deficiency. *European Journal of Biochemistry* **268**, 1876–1887.

Subramaniam S and Kleywegt GJ (2022) A paradigm shift in structural biology. *Nature Methods* **19**, 20–23.

Tian J, Bryk R, Itoh M, Suematsu M and Nathan C (2005) Variant tricarboxylic acid cycle in *Mycobacterium tuberculosis*: Identification of α-ketoglutarate decarboxylase. *Proceedings of the National Academy of Sciences of the United States of America* **102**, 10670–10675.

Tung CH, Huang JW and Yang JM (2007) Kappa-alpha plot derived structural alphabet and BLOSUM-like substitution matrix for rapid search of protein structure database. *Genome Biology* **8**, R31.

Vang JY, Breceda Jr. C, Her C and Krishnan VV (2022) Enzyme kinetics by real-time quantitative NMR (qNMR) spectroscopy with progress curve analysis. *Analytical Biochemistry* **658**, 114919.

Velázquez-Campoy A, Ohtaka H, Nezami A, Muzammil S and Freire E (2004) Isothermal titration calorimetry. *Current Protocols in Cell Biology* **23**, 17.7.1–22.4.52.

Vieira OV, Botelho RJ and Grinstein S (2002). Phagosome maturation: aging gracefully. *Biochemical Journal* **366**, 689–704.

Volesky B, Luong JHT and Aunstrup K (1984) Microbial enzymes: production, purification, and isolation. *Critical Reviews in Biotechnology* **2**, 119–146.

Wagner T, Bellinzoni M, Wehenkel A, O'Hare HM and Alzari PM (2011) Functional plasticity and allosteric regulation of α-ketoglutarate decarboxylase in central mycobacterial metabolism. *Chemistry & Biology* **18**, 1011–1020.

Wang HW and Wang JW (2016) How cryo-electron microscopy and X-ray crystallography complement each other. *Protein Science* **26**, 32–39.

Ward LD (1985) Measurement of ligand binding to proteins by fluorescence spectroscopy. *Methods in Enzymology* **117**, 400–414.

Warner DF (2015) *Mycobacterium tuberculosis* metabolism. *Cold Spring Harbor Perspectives in Medicine* **5**, a021121.

Wright BE, Butler MH and Able KR (1992) Systems analysis of the tricarboxylic acid cycle in Dictyostelium discoideum. I. The basis for model construction. *Journal of Biological Chemistry* **267**, 3101–3105.

Xu Y, Pooja, Borah K (2022) *Mycobacterium tuberculosis* carbon and nitrogen metabolic fluxes. *Bioscience Reports* **42**, BSR20211215.

Yang JM and Tung CH (2006) Protein structure database search and evolutionary classification. *Nucleic Acids Research* **34**, 3646–3659.

Ye J and Medzhitov R (2019) Control strategies in systemic metabolism. *Nature Metabolism* **1**, 947–957.

Zhao Z, Zhao L, Kong C, Zhou J and Zhou F (2024) A review of biophysical strategies to investigate protein-ligand binding: what have we employed? *International Journal of Biological Macromolecules* **276**, 133973.

Zhou M, Xie L, Yang Z, Zhou J and Xie J (2017) Lysine succinylation of *Mycobacterium tuberculosis* isocitrate lyase (ICL) fine-tunes the microbial resistance to antibiotics. *Journal of Biomolecular Structure and Dynamics* **35**, 1030–1041.

Figure 1

Figure 2

Figure 3

(a) Simultaneous monitoring of substrates and products

(b) Reaction time course

Figure 4

Figure 5

Figure 6